{"disease":{"id":"recurrent-metastatic-squamous-cell-carcinoma-of-head-neck","name":"recurrent metastatic squamous cell carcinoma of head neck"},"drugs":{"marketed":[{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02369874","title":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02319044","title":"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02207530","title":"Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06640725","title":"Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Groupe Oncologie Radiotherapie Tete et Cou","has_results":false},{"nct_id":"NCT03620123","title":"A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT04815720","title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Vaccinex Inc.","has_results":false},{"nct_id":"NCT05271604","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"BioAtla, Inc.","has_results":false},{"nct_id":"NCT03198130","title":"An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04454489","title":"Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}